查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1468506

2024-2032 年按药物类别（多奈哌齐、加兰他敏、卡巴拉汀、美金刚等）、配销通路（医院药房、零售药房、网上商店等）和地区分類的阿兹海默症药物市场报告

Alzheimer's Drugs Market Report by Drug Class (Donepezil, Galantamine, Rivastigmine, Memantine, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球阿兹海默症药物市场规模达77亿美元。阿兹海默症盛行率的上升、药物开发的众多进步以及神经退化性疾病研究的公共和私人资金的增加是推动市场的一些主要因素。

阿兹海默症药物是指专门用于减轻阿兹海默症症状或减缓其进展的药物化合物和疗法，阿兹海默症是一种常见的神经退化性疾病，主要影响认知功能。他们的目标是解决大脑中潜在的病理生理变化，例如淀粉样蛋白斑块和 tau 蛋白缠结的积累，这是阿兹海默症的特征。它们分为两大类，包括胆碱酯酶抑制剂和 NMDA 受体拮抗剂。胆碱酯酶抑制剂，如多奈哌齐、卡巴拉汀和加兰他敏，透过提高大脑中神经传导物质的水平来发挥作用，暂时增强认知功能。 NMDA 受体拮抗剂（例如美金刚）可调节麸胺酸活性，有助于缓解认知和行为症状。

阿兹海默症的盛行率不断上升，需要有效的治疗，这将刺激预测期内阿兹海默症药物市场的成长。此外，由于神经科学的许多进步以及对疾病潜在机制的更深入了解，主要参与者不断加强研究和开发力度，从而发现了潜在的治疗药物，这对市场成长产生了积极影响。此外，政府和组织对神经退化性疾病研究的资金分配增加，为药物开发创造了有利的环境，从而促进了市场成长。除此之外，不断扩大的老化人口（特别是在已开发地区）正在推动市场成长，因为老年人更容易罹患阿兹海默症。此外，新药和疗法的监管审批不断增加，为製药公司进入和扩大业务创造了机会，也促进了市场成长。

阿兹海默症药物市场趋势/驱动因素：

该疾病盛行率上升

阿兹海默症患者病率不断上升是支持市场成长的关键因素之一。这可以归因于全球人口快速老化。随着人们寿命的延长，包括阿兹海默症在内的与年龄相关的神经退化性疾病的发生率激增。这种人口结构的变化给全球医疗保健系统带来了不断增加的负担，因此需要有效的治疗。製药公司正在透过投资开发可以缓解症状或可能减缓疾病进展的药物来满足这一需求。此外，随着更多病例的发现，认识的提高和早期诊断也导致盛行率上升。因此，患病率因素推动了市场，并强调了迫切需要研究和创新来解决阿兹海默症带来的医疗保健挑战。

研究进展迅速

在分子和细胞层面对阿兹海默症的理解的进步是市场的关键驱动力。研究人员正在揭示疾病背后的复杂机制，包括淀粉样蛋白斑块和 tau 蛋白缠结在大脑退化中的作用。这些见解为药物开发提供了有价值的目标。此外，遗传学研究揭示了增加阿兹海默症易感性的遗传因素，进一步指导了药物发现工作。基因组学、神经影像学和生物标记分析等尖端技术正在促进临床试验和药物疗效评估。这些研究驱动的发展有助于扩大潜在阿兹海默症药物的种类并提高其有效性，为改善患者的治疗结果带来希望。

增加政府资金和支持

全球各国政府和医疗机构越来越意识到阿兹海默症是一场公共卫生危机。该疾病造成的巨大经济和社会影响，包括护理人员负担和医疗费用，导致阿兹海默症研究和药物开发计划的资金增加。对製药公司的政府资助、研究合作和激励措施变得更加普遍。这笔资金支持了正在进行的研究工作，并鼓励製药业投资阿兹海默症药物开发。此外，监管机构正在简化阿兹海默症药物的审批流程，促进更快的市场进入。在这种公共和私营部门支持的协作环境中，製药公司受到激励进行创新，并将有效的阿兹海默症治疗推向市场，以满足紧迫的全球医疗保健需求。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球阿兹海默症药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依药物类别

  • 多奈哌齐
    • 市场走向
    • 市场预测
  • 加兰他敏
    • 市场走向
    • 市场预测
  • 卡巴拉汀
    • 市场走向
    • 市场预测
  • 美金刚
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按配销通路

  • 医院药房
    • 市场走向
    • 市场预测
  • 零售药房
    • 市场走向
    • 市场预测
  • 网上商店
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 9 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 10 章：价值链分析

第 11 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 12 章：价格分析

第13章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbvie Inc.
    • AstraZeneca PLC
    • Biogen Inc.
    • Daiichi Sankyo Company Limited
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • H. Lundbeck A/S
    • F. Hoffmann-La Roche AG
    • Merck & Co. Inc.
    • Novartis AG
    • Ono Pharmaceutical Co. Ltd.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Limited
Product Code: SR112024A2695

The global Alzheimer's drugs market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.3% during 2024-2032. The rising prevalence of Alzheimer's disease, numerous advancements in drug development, and increasing public and private funding for neurodegenerative disease research are some of the major factors propelling the market.

Alzheimer's drugs refer to pharmaceutical compounds and therapies specifically designed to mitigate the symptoms or slow the progression of Alzheimer's disease, a prevalent neurodegenerative disorder that primarily affects cognitive functions. They aim to address the underlying pathophysiological changes in the brain, such as the accumulation of amyloid plaques and tau tangles, which are characteristic of Alzheimer's disease. They fall into two main categories, including cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, like donepezil, rivastigmine, and galantamine, work by boosting the levels of neurotransmitters in the brain, enhancing cognitive function temporarily. NMDA receptor antagonists, such as memantine, regulate glutamate activity, aid in providing relief from cognitive and behavioral symptoms.

The rising prevalence of Alzheimer's disease that necessitates effective treatments will stimulate the growth of the Alzheimer's drugs market during the forecast period. Moreover, the increasing research and development efforts by key players due to numerous advancements in neuroscience and a deeper understanding of the disease's underlying mechanisms, leading to the discovery of potential therapeutic agents, is positively influencing market growth. Additionally, the rise in funding allocations by governments and organizations for neurodegenerative disease research, facilitating a conducive environment for drug development, has catalyzed market growth. Besides this, the expanding aging population, particularly in developed regions, is propelling market growth as the elderly are more susceptible to Alzheimer's disease. Furthermore, the escalating regulatory approvals for novel drugs and therapies that creates opportunities for pharmaceutical companies to enter and expand their presence is contributing to market growth.

Alzheimer's Drugs Market Trends/Drivers:

Rising prevalence of the disease

The escalating prevalence of Alzheimer's disease is one of the key factors supporting the market growth. This can be attributed to the rapidly aging population worldwide. As people live longer, the incidence of age-related neurodegenerative disorders, including Alzheimer's, has surged. This demographic shift places an ever-increasing burden on global healthcare systems and necessitates effective treatments. Pharmaceutical companies are responding to this demand by investing in the development of drugs that can alleviate symptoms or potentially slow down disease progression. Moreover, heightened awareness and early diagnosis contribute to the rising prevalence as more cases are identified. As a result, the prevalence factor drives the market and underscores the urgent need for research and innovation to address the healthcare challenges posed by Alzheimer's disease.

Rapid advancements in research

Advances in the understanding of Alzheimer's disease at the molecular and cellular levels are pivotal drivers in the market. Researchers are unraveling the complex mechanisms behind the disease, including the role of amyloid plaques and tau protein tangles in brain degeneration. These insights provide valuable targets for drug development. Additionally, genetics research is revealing the hereditary factors that increase susceptibility to Alzheimer's, further guiding drug discovery efforts. Cutting-edge technologies, such as genomics, neuroimaging, and biomarker analysis, are facilitating clinical trials and drug efficacy assessments. These research-driven developments are instrumental in expanding the repertoire of potential Alzheimer's drugs and enhancing their effectiveness, offering hope for improved patient outcomes.

Increasing government funding and support

Governments and healthcare organizations across the globe are increasingly recognizing Alzheimer's disease as a public health crisis. The substantial economic and social impact of the disease, including caregiver burden and healthcare costs, has led to a rise in funding for Alzheimer's research and drug development initiatives. Government grants, research partnerships, and incentives for pharmaceutical companies have become more prevalent. This financial support bolsters ongoing research efforts and encourages the pharmaceutical industry to invest in Alzheimer's drug development. Moreover, regulatory agencies are streamlining approval processes for Alzheimer's drugs, facilitating faster market entry. In this collaborative environment of public and private sector support, pharmaceutical companies are incentivized to innovate and bring effective Alzheimer's treatments to the market, addressing a pressing global healthcare need.

Alzheimer's Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global Alzheimer's drugs market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

Donepezil

Galantamine

Rivastigmine

Memantine

Others

Donepezil represents the most popular drug class

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes donepezil, galantamine, rivastigmine, memantine, and others. According to the report, donepezil represented the largest segment.

Donepezil is a medication categorized as a cholinesterase inhibitor, commonly used in the treatment of Alzheimer's disease. It works by increasing the levels of certain neurotransmitters in the brain, helping to improve cognitive function and alleviate some of the symptoms associated with Alzheimer's, such as memory loss, confusion, and problems with thinking and reasoning.

Furthermore, donepezil, along with similar drugs like rivastigmine and galantamine, plays a pivotal role in driving the market growth. These drugs are often prescribed to patients with Alzheimer's to manage their symptoms, providing relief and enhancing their quality of life. As the global prevalence of Alzheimer's continues to rise, there is an increasing demand for such drugs. This growing demand encourages pharmaceutical companies to invest in research and development, striving to innovate and improve upon existing treatments, thus contributing to the expansion of the Alzheimer's drugs market.

Breakup by Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Stores

Others

Hospital pharmacy accounts for the majority of the market share

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacy, retail pharmacy, online stores, and others. According to the report, hospital pharmacy accounted for the largest market share.

Hospital pharmacy refers to the specialized pharmacy practice within healthcare institutions, such as hospitals and medical centers. Its primary role is to ensure the safe and effective use of medications for inpatients and outpatients. Hospital pharmacists work closely with healthcare teams to provide medication therapy management, including drug dispensing, monitoring, and patient education. Hospital pharmacies play a crucial role in fueling the market expansion as they are instrumental in the distribution and administration of Alzheimer's medications. They serve as a pivotal link between pharmaceutical companies, healthcare providers, and patients, ensuring that Alzheimer's drugs reach the right individuals at the right time.

Moreover, hospital pharmacists contribute to patient education and adherence, optimizing the effectiveness of these drugs. The growth of the Alzheimer's drugs market is related to the efficient and patient-focused services provided by hospital pharmacies, as they facilitate the delivery of these vital medications to those in need.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest share in the market since the region has a significant and growing geriatric population, and Alzheimer's primarily affects older individuals. This demographic trend increases the demand for Alzheimer's drugs. Moreover, North America boasts a robust healthcare infrastructure, which includes advanced research facilities and pharmaceutical companies at the forefront of Alzheimer's drug development. These companies conduct clinical trials and research initiatives that contribute to innovation in the field.

Additionally, regulatory bodies like the FDA in the United States play a crucial role in drug approvals, setting the standard for global markets. Apart from this, North America has a high level of awareness about Alzheimer's disease, leading to early diagnosis and greater use of available treatments. Furthermore, North America's well-established healthcare reimbursement systems and patient advocacy groups actively support access to Alzheimer's drugs, fostering an environment that drives market growth and encourages pharmaceutical innovation in the region.

Competitive Landscape:

Key players in the Alzheimer's drugs industry have been instrumental in driving recent innovations. Notably, a groundbreaking FDA-approved drug from one of these major pharmaceutical companies directly targets amyloid plaques, marking a significant advancement in Alzheimer's treatment. Other key players are pioneering therapies that enhance amyloid clearance and simultaneously address tau pathology, both of which have shown promise in clinical trials. Beyond traditional drug development, these companies are exploring innovative approaches, including anti-inflammatory drugs, to combat neuroinflammation associated with Alzheimer's. Additionally, digital health technologies have been integrated into their strategies, with the introduction of cognitive assessment tools and digital biomarkers, revolutionizing early detection and monitoring of Alzheimer's. The efforts of these industry players signify a dynamic and comprehensive approach to tackle this complex neurodegenerative disease.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

AstraZeneca PLC

Biogen Inc.

Daiichi Sankyo Company Limited

Eisai Co. Ltd.

Eli Lilly and Company

H. Lundbeck A/S

F. Hoffmann-La Roche AG

Merck & Co. Inc.

Novartis AG

Ono Pharmaceutical Co. Ltd.

Pfizer Inc

Teva Pharmaceutical Industries Limited

Recent Developments:

In July 2023, AbbVie Inc., a leading global biopharmaceutical company, announced the expansion of its strategic collaboration with Calibr, a nonprofit drug discovery division of Scripps Research. This collaboration aims to propel the development of multiple preclinical and early-stage clinical assets in the field of biopharmaceuticals. Building upon their existing partnership, this expansion signifies a commitment to advancing innovative therapies for various diseases.

In March 2021, Biogen Inc. and Eisai Co., Ltd. expanded their existing collaboration agreement on the treatments of Alzheimer's disease. This expansion underscores their shared commitment to addressing one of the most challenging and pressing healthcare issues of our time. Both companies bring unique strengths to the table: Biogen's expertise in neuroscience and drug development, combined with Eisai's deep-rooted knowledge in the field of dementia and Alzheimer's disease, creates a powerful synergy.

In September 2022, Eisai Co., Ltd. and Biogen Inc. reported positive topline results from their global Phase 3 Clarity AD clinical trial of lecanemab. Lecanemab is an investigational antibody designed to target amyloid beta (AB) protofibrils, and it holds promise as a potential treatment for individuals with mild cognitive impairment (MCI) due to Alzheimer's disease and mild Alzheimer's disease. This development marks a significant milestone in the pursuit of effective Alzheimer's treatments. The positive results suggest that lecanemab has shown potential in addressing the underlying pathology of Alzheimer's disease by targeting AB protofibrils, which are thought to contribute to disease progression.

Key Questions Answered in This Report:

  • How has the global alzheimer's drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global alzheimer's drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global alzheimer's drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Alzheimer's Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Donepezil
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Galantamine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Rivastigmine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Memantine
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Stores
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbvie Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca PLC
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Biogen Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Daiichi Sankyo Company Limited
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Eisai Co. Ltd.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Eli Lilly and Company
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 H. Lundbeck A/S
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 F. Hoffmann-La Roche AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Novartis AG
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Ono Pharmaceutical Co. Ltd.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Pfizer Inc.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
    • 13.3.13 Teva Pharmaceutical Industries Limited
      • 13.3.13.1 Company Overview
      • 13.3.13.2 Product Portfolio
      • 13.3.13.3 Financials
      • 13.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Alzheimer's Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Alzheimer's Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Alzheimer's Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 4: Global: Alzheimer's Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 5: Global: Alzheimer's Drugs Market: Breakup by Region (in %), 2023
  • Figure 6: Global: Alzheimer's Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: Alzheimer's Drugs (Donepezil) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Alzheimer's Drugs (Donepezil) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Alzheimer's Drugs (Galantamine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Alzheimer's Drugs (Galantamine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Alzheimer's Drugs (Rivastigmine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Alzheimer's Drugs (Rivastigmine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Alzheimer's Drugs (Memantine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Alzheimer's Drugs (Memantine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Alzheimer's Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Alzheimer's Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Alzheimer's Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Alzheimer's Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Alzheimer's Drugs (Retail Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Alzheimer's Drugs (Retail Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Alzheimer's Drugs (Online Stores) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Alzheimer's Drugs (Online Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Alzheimer's Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Alzheimer's Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: North America: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: North America: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: United States: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: United States: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Canada: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Canada: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Asia Pacific: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Asia Pacific: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: China: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: China: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Japan: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Japan: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: India: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: India: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: South Korea: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: South Korea: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Australia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Australia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Indonesia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Indonesia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Europe: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Europe: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Germany: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Germany: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: France: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: France: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: United Kingdom: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: United Kingdom: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Italy: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Italy: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Spain: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Spain: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Russia: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Russia: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Latin America: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Latin America: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Brazil: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Brazil: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Mexico: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Mexico: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Others: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Others: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Middle East and Africa: Alzheimer's Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Middle East and Africa: Alzheimer's Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Global: Alzheimer's Drugs Industry: SWOT Analysis
  • Figure 74: Global: Alzheimer's Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Alzheimer's Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Alzheimer's Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Alzheimer's Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Alzheimer's Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: Alzheimer's Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Alzheimer's Drugs Market: Competitive Structure
  • Table 6: Global: Alzheimer's Drugs Market: Key Players